The Oncology Institute(US:TOI) Globenewswire·2025-11-04 22:06Core Insights - Topicus.com Inc. reported a total revenue of €387.9 million for Q3 2025, marking a 24% increase compared to €312.2 million in Q3 2024, primarily driven by acquisitions and organic growth of 3% [4][6] - The company experienced a net loss of €120.9 million in Q3 2025, a significant decline from a net income of €38.0 million in the same quarter of 2024, largely due to a €221.7 million expense related to the investment in Asseco [5][6] - Cash flows from operations increased by 53% to €48.4 million in Q3 2025 compared to €31.7 million in Q3 2024, while free cash flow available to shareholders rose by 114% to €22.3 million [6][7] Financial Performance - Total revenue for the first nine months of 2025 reached €1,115.5 million, a 20% increase from €930.0 million in the same period of 2024 [4] - The net loss for the nine months ended September 30, 2025, was €9.3 million, compared to a net income of €93.3 million for the same period in 2024 [5] - Cash flows from operations for the nine months increased by 14% to €304.9 million compared to €268.0 million in 2024 [7] Cash Flow and Investments - Free cash flow available to shareholders for the nine months ended September 30, 2025, increased by 19% to €167.5 million from €140.7 million in 2024 [7] - The company completed acquisitions for a total cash consideration of €11.4 million, with deferred payments estimated at €7.8 million, leading to a total consideration of €19.2 million [6] Shareholder Metrics - The net loss per share for Q3 2025 was €0.94, compared to earnings of €0.28 per share in Q3 2024 [5][6] - The weighted average shares outstanding for Q3 2025 were 83,338,874, slightly up from 82,912,026 in Q3 2024 [17]